PUBLISHER: The Business Research Company | PRODUCT CODE: 1945402
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945402
Interventional tumor ablation is a minimally invasive procedure that utilizes image-guided techniques to target and destroy cancerous or benign tumors without the need for open surgery. It uses thermal or non-thermal energy to eliminate tumor cells while minimizing damage to surrounding healthy tissue. This procedure is often employed when surgery is not viable or as an alternative to traditional treatments.
The main product types in interventional tumor ablation include open surgery, minimally invasive surgery, and image-guided interventions. Open surgery involves making an incision in the body to access and treat the affected area, typically using scalpels and other instruments. Key technologies in this field include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and high-intensity focused ultrasound (HIFU). Device types used in these procedures include ablation systems, consumables, support devices, and imaging systems. Tumor ablation is frequently applied to liver, kidney, lung, and bone tumors. The end users of these technologies range from hospitals and specialized cancer treatment centers to ambulatory surgical centers and research institutes.
Tariffs are influencing the interventional tumor ablation market by increasing costs of imported ablation probes, imaging systems, electronic control units, and specialized medical components used in rfa, mwa, cryoablation, and hifu systems. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported high-end medical devices, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing capital expenditure and slowing equipment replacement cycles. However, they are also encouraging local manufacturing, regional device assembly, and innovation in cost-optimized ablation technologies.
The interventional tumor ablation market research report is one of a series of new reports from The Business Research Company that provides interventional tumor ablation market statistics, including interventional tumor ablation industry global market size, regional shares, competitors with a interventional tumor ablation market share, detailed interventional tumor ablation market segments, market trends and opportunities, and any further data you may need to thrive in the interventional tumor ablation industry. This interventional tumor ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The interventional tumor ablation market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rising global cancer incidence, advancement of medical imaging technologies, increasing preference for minimally invasive therapies, expansion of interventional oncology practices, improved clinical outcomes of ablation procedures.
The interventional tumor ablation market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing integration of ai-assisted imaging guidance, rising adoption of personalized cancer treatment, expansion of ambulatory surgical centers, growing investments in oncology device innovation, increasing demand for cost-effective cancer therapies. Major trends in the forecast period include increasing adoption of minimally invasive tumor ablation procedures, rising use of image-guided ablation technologies, expansion of microwave and radiofrequency ablation systems, growing demand for outpatient cancer treatments, enhanced focus on precision oncology.
The increasing incidence of cancer is expected to drive the growth of the interventional tumor ablation market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and spread to other parts of the body through the blood and lymphatic systems. The rising occurrence of cancer is largely attributed to lifestyle and environmental factors, including smoking, unhealthy diets, obesity, and exposure to carcinogenic substances. Interventional tumor ablation supports cancer treatment by providing minimally invasive therapeutic options that serve as alternatives to conventional surgery. These techniques shorten treatment durations and recovery times by enabling precise tumor destruction, thereby improving patient outcomes and quality of life. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, more than 35 million new cancer cases are projected globally by 2025, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is contributing to the expansion of the interventional tumor ablation market.
Leading companies operating in the interventional tumor ablation market are concentrating on the development of advanced technological solutions, such as BioTrace software suites, to improve procedural accuracy and enhance treatment effectiveness. BioTrace software suites are integrated platforms designed to track, manage, and analyze biological and clinical data, particularly within healthcare and research settings. For example, in July 2024, TechsoMed Medical Technologies Ltd., an Israel-based medical device manufacturer, introduced BioTraceIO Vision and BioTraceIO Precision, software solutions developed for image-guided liver tumor ablation therapy. BioTraceIO Vision utilizes artificial intelligence-driven personalized treatment planning and assessment tools based on standard medical imaging to increase the precision and efficiency of liver tumor ablation. BioTraceIO Precision offers real-time ultrasound-based visualization and predictive mapping of the ablation zone during and after procedures, enabling clinicians to evaluate tissue damage and treatment outcomes with strong correlation to 24-hour post-ablation computed tomography scans.
In February 2024, Immunophotonics Inc., a US-based biotechnology company, entered into a partnership with AngioDynamics Inc. This collaboration is intended to combine Immunophotonics' lead immunotherapy candidate, IP-001, with AngioDynamics' ablation technologies to investigate the potential of integrating ablation with immunotherapy for the treatment of solid tumor cancers. AngioDynamics Inc. is a US-based medical device company that provides microwave and radiofrequency ablation systems for minimally invasive cancer therapies.
Major companies operating in the interventional tumor ablation market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, EDAP TMS S.A., Elekta AB, AngioDynamics Inc., InSightec Ltd., Cascination AG, IceCure Medical Ltd., Theraclion SA, Mermaid Medical Group A/S, H.S. Hospital Service S.p.A., Varian Medical Systems Inc., Neuwave Medical, BTG plc, MedWaves Inc., Perseon Medical AB, Chongqing Haifu Medical Technology Co. Ltd., AngioDynamics Nanoknife Division, Galil Medical Inc.
North America was the largest region in the interventional tumor ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional tumor ablation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the interventional tumor ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The interventional tumor ablation market consists of revenues earned by entities by providing services such as electroporation, tumor biopsy services, thermal ablation monitoring, and post-ablation follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional tumor ablation market also includes sales of radiofrequency ablation (RFA) generators, microwave ablation (MWA) systems, cryoablation probes, laser fibers and electrode needles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Interventional Tumor Ablation Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses interventional tumor ablation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for interventional tumor ablation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interventional tumor ablation market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.